{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:28:46Z","timestamp":1771928926404,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hormone receptor\u2013positive (HR+) endometrial carcinoma (EC) responds to endocrine therapy, but clinical benefit duration is often limited, especially in patients with widely metastatic or recurrent disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>A 54-year-old woman with HR-high (ER\/PR 90%) metastatic EC (FIGO IIIC2) discontinued adjuvant chemotherapy due to severe toxicity. She initiated megestrol acetate and letrozole in March 2017, achieving stable disease (SD) for 38 months. Self-discontinuation (January\u2013July 2020) led to disease progression (new retroperitoneal lymph nodes), but resuming full-dose therapy restored SD for 49 months. After dose reduction (July 2023), the disease progressed again at 12 months; re-escalation to full dose induced regression. At last follow-up (OS: 108 months), she maintained SD with minimal toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first case demonstrating that full-dose megestrol acetate plus letrozole may induce durable antitumor activity in HR-high expression metastatic EC, warranting prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1729721","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:44:52Z","timestamp":1771926292000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term control for &gt; 9 years with megestrol acetate-letrozole: metastatic endometrioid carcinoma case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Lixia","family":"Liu","sequence":"first","affiliation":[{"name":"Shanxi Province Cancer Hospital\/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences\/Cancer Hospital Affiliated to Shanxi Medical University","place":["Shanxi, Taiyuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Ma","sequence":"additional","affiliation":[{"name":"Shanxi Province Cancer Hospital\/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences\/Cancer Hospital Affiliated to Shanxi Medical University","place":["Shanxi, Taiyuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[{"name":"The Genetic Analysis Department, YuceBio Technology Co., Ltd.","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenguang","family":"He","sequence":"additional","affiliation":[{"name":"Shanxi Province Cancer Hospital\/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences\/Cancer Hospital Affiliated to Shanxi Medical University","place":["Shanxi, Taiyuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0038","article-title":"NCCN guidelines\u00ae Insights: uterine neoplasms, version 3.2025","volume":"23","author":"Abu-Rustum","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.07.002","article-title":"Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis","volume":"147","author":"Ethier","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.12.031","article-title":"A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study","volume":"164","author":"Slomovitz","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ygyno.2003.09.018","article-title":"Gynecologic Oncology Group study. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Whitney","year":"2004","journal-title":"Gynecol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nature14583","article-title":"Progesterone receptor modulates ER\u03b1 action in breast cancer","volume":"523","author":"Mohammed","year":"2015","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1048-891X.2004.14419.x","article-title":"The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Ma","year":"2004","journal-title":"Int J Gynecol Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10549-007-9696-3","article-title":"The discovery and mechanism of action of letrozole","author":"Bhatnagar","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"B11","article-title":"Preliminary studies of aromatase in human neoplastic endometrium","volume":"63","author":"Tseng","year":"1984","journal-title":"Obstet Gynecol"},{"key":"B12","first-page":"491","article-title":"Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies","volume":"146","author":"Watanabe","year":"1995","journal-title":"Am J Pathol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1055\/s-0029-1242998","article-title":"Role of progesterone in endometrial cancer","volume":"28","author":"Kim","year":"2010","journal-title":"Semin Reprod Med"},{"key":"B14","article-title":"Abstract PS15-06: Results of the window-of-opportunity PIONEER trial evaluating addition of the progesterone receptor (PR) agonist megestrol to letrozole for early stage estrogen receptor (ER) positive breast cancer: exploiting ER-PR interaction","author":"Burrell","year":"","journal-title":"Cancer research"},{"key":"B15","doi-asserted-by":"publisher","first-page":"407.e1","DOI":"10.1016\/j.ajog.2021.05.007","article-title":"Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer","volume":"225","author":"van Weelden","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143504","article-title":"Drug holidays and overall survival of patients with metastatic colorectal cancer","volume":"13","author":"Garattini","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamaoncol.2020.5774","article-title":"Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: A nonrandomized clinical trial","volume":"7","author":"Atallah","year":"2021","journal-title":"JAMA Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1779","article-title":"Circulating tumor DNA-guided de-escalation targeted therapy for advanced non\u2013small cell lung cancer: A nonrandomized controlled trial","volume":"10","author":"Dong","year":"2024","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.017","article-title":"Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy\u2606","volume":"32","author":"Jerusalem","year":"2021","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16447","article-title":"Optimal treatment of hormone receptor-positive advanced breast cancer patients with palbociclib","volume":"43","author":"Morita","year":"2023","journal-title":"Anticancer Res"},{"key":"B21","unstructured":"Niravath\n              PA\n            \n          \n          clinicaltrials.gov\n          Phase II trial of fulvestrant plus abemaciclib in er-positive, her2-negative metastatic breast cancer immediately after failure of A cdk4&x2F;6 inhibitor\n          \n          2025"},{"key":"B22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ygyno.2024.01.018","article-title":"Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis","volume":"182","author":"Casanova","year":"2024","journal-title":"Gynecologic Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1999","article-title":"A phase II study of fulvestrant plus abemaciclib in hormone receptor\u2013positive advanced or recurrent endometrial cancer","volume":"31","author":"Green","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004739","article-title":"The promise of combining CDK4\/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma","volume":"33","author":"Ray-Coquard","year":"2023","journal-title":"Int J Gynecological Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061763","article-title":"CDK4\/6 inhibitors\u2014Overcoming endocrine resistance is the standard in patients with hormone receptor-positive breast cancer","volume":"15","author":"Nabieva","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1729721\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:44:56Z","timestamp":1771926296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1729721\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":25,"alternative-id":["10.3389\/fonc.2026.1729721"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1729721","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"1729721"}}